Kiromic BioPharma, Inc. (KRBP)
| Market Cap | 3.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.80M |
| Shares Out | 1.54M |
| EPS (ttm) | -18.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 700 |
| Open | 2.050 |
| Previous Close | 2.150 |
| Day's Range | 2.050 - 2.240 |
| 52-Week Range | 0.160 - 4.080 |
| Beta | 2.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 13, 2023 |
About KRBP
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L... [Read more]
Financial Performance
Financial StatementsNews
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 cl...
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase 1 cl...
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Company...
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the...
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients.
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial.
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing primary lung tumor stabilization and the complete di...
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as th...
Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerf...
Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces continued encouraging clinical findings from the most recent follow-up visit of th...
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
HOUSTON--(BUSINESS WIRE)---- $KRBP #Celltherapy--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable early efficacy results from the first patient enrolled in the Phas...
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)---- $KRBP #BIOTECH--Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial.
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer.
Kiromic BioPharma Announces Uplisting to OTCQB Market
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma Announces Uplisting to OTCQB Market.
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artif...
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMON...
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial in...
Kiromic BioPharma Welcomes Two New Directors to its Board
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artific...
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer.
Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® ...
Kiromic BioPharma Announces Reverse Stock Split
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artifici...
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc.
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® ...
Kiromic BioPharma CEO Issues Letter to Stockholders
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artifici...
SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects
SAN FRANCISCO , Nov. 8, 2022 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP) relating to...